On January 31st, the Department of Health and Human Services Office of the Inspector General (HHS-OIG) issued a proposed rule that would modify certain provisions of the federal Anti-Kickback Statute that protect rebating arrangements that are used in the pharmaceutical supply chain. Changing these rules has the potential to bring price relief to consumers who are struggling to afford their medications due to escalating pharmaceutical costs, but this proposal also has the potential to create unintended consequences that could cause costs to rise for all consumers. Aimed Alliance has submitted a comment in response to this proposal. We voiced our support for this proposed rule but cautioned HHS-OIG to proceed carefully to ensure that the proposal functions as intended and achieves savings for consumers.
Last Updated on May 14, 2020 by Aimed Alliance
